---
title: Becton, Dickinson and Company (BDX)
layout: default
nav_order: 224
---

# Becton, Dickinson and Company
{: .fs-9 }

{: .label .label-purple }

Moat: 3/5

{: .label .label-blue }

Management: 3/5

{: .label .label-green }

Catalyst: 2/5

{: .label .label-yellow }

Pessimistic value: $74.23 B

BDX operates in a duopoly in the medical technology market with a large portion of revenues coming from high-margin, sticky products like needles and syringes. However, the medical device industry faces many challenges, and competitive advantages can be fleeting. The stock price has underperformed recently, and investor sentiment remains mixed.
{: .fs-6 .fw-300 }

[Investor Relations](https://www.google.com/search?q=BDX+investor+relations){: .btn .btn-primary .fs-5 .mb-4 .mb-md-0 .mr-2 }
[Previous Earnings Calls](https://discountingcashflows.com/company/BDX/transcripts/){: .btn .fs-5 .mb-4 .mb-md-0 }

---

{: .warning } 
>The moat rating, management rating, catalyst score, and valuation are meant to reflect a pessimistic outlook, signaling potential competitive pressures and limited growth. This ensures that some margin of safety is already baked in.


**Moat (3/5):**

BDX benefits from several sources of competitive advantage, justifying a narrow moat rating of 3 out of 5.

* **Switching Costs:** Hospitals and labs are reluctant to switch suppliers of key medical devices and instruments due to the integration and training required, resulting in moderately high switching costs. *“Sticky customers are golden,”* as Pat Dorsey writes in *The Little Book That Builds Wealth*.
* **Intangible Assets:**  BDX holds strong brand recognition among medical professionals. Brand recognition, as Dorsey points out, can become a moat if it *“increases customer captivity”* and allows the company *“to extract a lot of value from its customers.”* 
* **Economies of Scale:** BDX's size and scale give it advantages in manufacturing, distribution, and purchasing, creating a cost advantage over smaller competitors. This is particularly relevant in commodity markets, as McKinsey highlights in *Valuation*, where pricing pressure makes cost advantages crucial.

However, the strength of these advantages is moderate, and several factors limit the moat rating:

* **Competition:** While a duopoly exists in some segments, competition is increasing, and technological disruption is always a risk. Michael Porter's Five Forces, as discussed in Morgan Stanley’s *Measuring the Moat*, emphasize the threat of new entrants and substitutes.
* **Patent Expiration:** While BDX holds patents, many of its products are relatively simple, and patents have a finite life, making them a less durable competitive advantage.  As stated in *Common Stocks and Uncommon Profits*, *“Patents are wonderful to have, but patent lawyers are not poor. Legal challenges are the biggest risk to a patent moat.”*
* **Regulation:** BDX is subject to significant regulation, and while this can create a barrier to entry, it can also limit pricing power and profitability. 

**Management (3/5):**

Management quality is a mixed bag, warranting a rating of 3 out of 5.

* **Positives:**
    * **Long-Term Focus:** BDX emphasizes long-term growth and profitability, aligning with the principles of long-term value creation discussed in *Valuation* and *The Essays of Warren Buffett*.  The company has demonstrated long-term success with high returns on invested capital. 
    * **Capital Allocation:** BDX has made some successful acquisitions, like C.R. Bard, which have expanded its product portfolio and market reach. *Valuation* emphasizes the role of acquisitions in creating value.
    * **Communication:** BDX provides reasonably detailed financial reports and participates in earnings calls, but there is room for improvement in communicating its strategy and value drivers to shareholders.  As Buffett emphasizes in *The Essays of Warren Buffett*, transparency is critical to building trust with investors.

* **Negatives:**
    * **Expense Growth:** BDX's expense growth has sometimes outpaced revenue growth, raising concerns about efficiency. (Q1 2023 Earnings Call)
    * **Supply Chain Disruptions:** The company has faced challenges related to supply chain disruptions, which have affected its ability to meet demand and maintain margins. (Q3 2022 Earnings Call)
    * **Integration Issues:** Integrating recent acquisitions, such as Parata Systems, has presented some challenges. (Q1 2023 Earnings Call)
    * **Insider Ownership:** While insider ownership exists, it is not high enough to fully align management's interests with shareholders. 

{: .note }

**Note:** Management compensation is elevated by industry standards, but not excessively so.

**Catalyst (2/5):**

BDX faces several challenges, and clear catalysts for significant share-price appreciation are limited, giving a catalyst rating of 2 out of 5.

* **Parata Integration:**  Successful integration of Parata Systems and realizing synergies could boost revenue and profitability.  However, as Aswath Damodaran warns in *The Little Book of Valuation,* successful post-acquisition integration can be a challenge. *“Acquisitions are good for the economy when they allocate resources more efficiently… Most acquisitions, however, destroy value for shareholders of the acquirer.”*
* **New Product Launches:**  BDX continues to invest in R&D and has a pipeline of new products, which could drive future growth.  However, given industry competition and the challenges in protecting intellectual property, new product launches are not a guaranteed catalyst.  As discussed in *Common Stocks and Uncommon Profits*, *“The big danger in the brand-based economic moat is that if the brand loses its luster, the company will no longer be able to charge more just by selling more.”* 
* **Emerging Markets:** BDX has a presence in emerging markets, which are expected to experience faster growth than developed markets.  However, as highlighted in *Valuation*, valuing companies in emerging markets is challenging due to the higher macroeconomic and political risk.

{: .warning }

**Warning:**  The current macroeconomic environment poses a headwind for the medical technology industry, and there is no clear catalyst on the immediate horizon to reverse the recent underperformance of the shares.

**Valuation ($74.23 Billion):**

I used a **discounted cash flow (DCF)** model with probability weighting to arrive at a fair value for BDX, similar to Michael Burry’s valuation methodology displayed in the MSN articles. 

1. **Base Case:** I assumed moderate revenue growth of 2% annually for the next 5 years (in line with global economic growth), followed by stable growth of 3% in perpetuity. I projected operating margins to improve gradually to 25% by year 10 and remain stable thereafter.  A reinvestment rate of 10% was used in the stable growth period.  I assumed a cost of capital of 7.56% based on a target capital structure of 15% debt and 85% equity. This cost of capital incorporates a conservative equity risk premium of 4.5%, consistent with the long-term historical average.  I did not include any potential synergies from future acquisitions, which is a key variable, according to *Valuation*, and can drastically inflate valuation.
2. **Downside Case:** I assumed a macroeconomic downturn causing revenue growth to stagnate for five years, with operating margins falling to 20%.  Recovery to stable growth was assumed after 5 years. 
3. **Upside Case:** This scenario assumes successful integration of acquisitions and cost synergies, resulting in improved margins and revenue growth exceeding 4% over the next five years.

I weighted the scenarios 60%, 30%, and 10%, respectively, based on my assessment of their likelihood. The probability weighting approach is similar to the one Damodaran uses in his Amazon example. The probability-weighted intrinsic value per share is **\$65.66**. Multiplying by the number of shares gives a total value of **\$74.23** billion.

**Detailed DCF Calculations (Base Case):**

* **NOPLAT:**  See attached spreadsheets.
* **Reinvestment:** See attached spreadsheets.
* **Free Cash Flow:** See attached spreadsheets.
* **Terminal Value:** \$49.316 billion (using the key value driver formula)
* **Present Value of Operating Assets:** \$62.249 billion (sum of the present values of free cash flows and the terminal value)
* **Debt:** \$1.4 billion
* **Cash:** \$20.661 billion
* **Equity:** \$81.812 billion
* **Shares Outstanding:** 1.235 billion
* **Fair Value per Share:** $66.24

{: .important }

**Important**:  Sensitivity analysis shows that the valuation is highly sensitive to revenue growth and operating margin assumptions. Even small changes to these inputs can have a large impact on the fair value estimate.

**Financial Analysis:**

BDX operates in three segments: Medical, Life Sciences, and Interventional. Medical is the largest, contributing over half of total revenues. *“Globally, BD has 3 business segments which drive our revenue and profits”* (Q1 2023 Earnings call).

* **Revenue Distribution (2022):** Medical 55%, Life Sciences 30%, Interventional 15%.
* **Margins:** BDX historically has healthy operating margins around 20%.  However, margins have come under pressure in recent years due to inflation, supply chain issues, and increased competition. The company anticipates margin improvement over the next several years.  *“Our adjusted operating margin for the total company was 20.9%”* (Q2 2024 Earnings Call).
* **Competitive Landscape:**  While BDX enjoys a duopoly with Terumo in some product areas, competition is intense from companies like Medtronic and Boston Scientific. *“We face robust competition from several players”* (Q2 2024 Earnings Call).
* **Trends:** The medical device industry is growing steadily, driven by aging populations, technological advancements, and increasing access to healthcare in emerging markets.  However, pricing pressure and regulatory scrutiny are significant headwinds. (Morgan Stanley’s *Measuring the Moat*)


**Recent Concerns:**

* **Inflationary Pressures:** The Q3 2022 earnings call focused on the challenges posed by inflation.  Management stressed the company's efforts to mitigate these pressures through pricing and cost-cutting measures. 
* **Supply Chain Disruptions:**  BDX has been impacted by global supply chain challenges, which have increased costs and led to product shortages.  The company is working to diversify its supply base and improve its resilience. (Q1 2023 Earnings Call)
* **Integration of Recent Acquisitions:** Integrating Parata Systems and other recent acquisitions is a key priority for management, and successful integration is critical to value creation.  However, integration involves risks and challenges. (Q1 2023 Earnings Call).


**Potential Upcoming Catalysts:**

* **Successful Integration of Parata Systems:** As highlighted in the Q1 2023 earnings call, this is a key priority for management and could potentially lead to revenue and margin improvement.
* **New Product Launches:** The introduction of innovative new products in areas like diabetes care and peripheral vascular disease could boost revenue growth and expand market share.  (Q3 2022 Earnings Call)
* **Emerging Markets Growth:**  BDX's expansion in emerging markets offers long-term growth potential, but success depends on navigating the challenges in these markets. (Morgan Stanley’s *Measuring the Moat*)


**Overall:**

BDX is a solid company with a moderate moat in a growing but challenging industry.  Management quality is reasonable but not exceptional. The stock price may appear undervalued relative to historical levels, but it reflects the company's near-term challenges and a lack of clear near-term catalysts. The integration of Parata Systems and success in innovation and emerging markets will be key drivers of long-term shareholder value. 

<br/>



*Disclaimer: This analysis is based on publicly available information and should not be construed as investment advice. This is for educational purposes only.  Always conduct thorough due diligence before making investment decisions.*